Nizal S. Chandrakumar

Array ( [id] => 19083099 [patent_doc_number] => 20240109900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => AZABICYCLIC SHP2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/264299 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18123356 [patent_doc_number] => 20230008966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/667289 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140431 [patent_doc_number] => 20240139214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 18/275445 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625715 [patent_doc_number] => 20220160730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH NEUROSTERIODS AND ANALOGUES THEREOF [patent_app_type] => utility [patent_app_number] => 17/592064 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749552 [patent_doc_number] => 20220227756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => SUBSTITUTED IMIDAZOQUINOLINES [patent_app_type] => utility [patent_app_number] => 17/590550 [patent_app_country] => US [patent_app_date] => 2022-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20882261 [patent_doc_number] => 12698292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Toxin molecule suitable for antibody-drug conjugate [patent_app_type] => utility [patent_app_number] => 18/274905 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4823 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18909250 [patent_doc_number] => 11872213 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Formulations [patent_app_type] => utility [patent_app_number] => 17/587510 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9548 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18383366 [patent_doc_number] => 11654130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders [patent_app_type] => utility [patent_app_number] => 17/586119 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 23177 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881091 [patent_doc_number] => 20220296568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => PAMOATE SALT OF MONOAMINE ANTI-PARKINSON'S AGENTS, METHOD OF PREPARATION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/586354 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631085 [patent_doc_number] => 20240409534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => CRYSTAL FORM OF METHYLPYRAZOLE-SUBSTITUTED PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/273991 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18777807 [patent_doc_number] => 11819481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity [patent_app_type] => utility [patent_app_number] => 17/582646 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 11318 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18210868 [patent_doc_number] => 20230057130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/579541 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720316 [patent_doc_number] => 20220213036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/578050 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17578050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733227 [patent_doc_number] => 20220218686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ANTIARRHYTHMIC FORMULATION [patent_app_type] => utility [patent_app_number] => 17/574901 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17574901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018864 [patent_doc_number] => 20240075035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA [patent_app_type] => utility [patent_app_number] => 18/271716 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837652 [patent_doc_number] => 20220274957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 17/573814 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875862 [patent_doc_number] => 20250108119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/271106 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 160846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18994584 [patent_doc_number] => 11911401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Tryptamine compositions for enhancing neurite outgrowth [patent_app_type] => utility [patent_app_number] => 17/570054 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 28940 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593177 [patent_doc_number] => 12150995 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => IRAK degraders and uses thereof [patent_app_type] => utility [patent_app_number] => 17/646556 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 255682 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 319 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970356 [patent_doc_number] => 20240050448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => Biodegradable Implant Including Naltrexone and Cholesterol [patent_app_type] => utility [patent_app_number] => 18/270682 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270682 [rel_patent_id] =>[rel_patent_doc_number] =>)